Navigation Links
Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market
Date:10/12/2010

CHARLOTTESVILLE, Va., Oct. 12 /PRNewswire/ -- Beta-Pro LLC, announced today that it has expanded its operations to accommodate increasing demands from pharmaceutical drug discovery and research institutes in the $2 billion hepatocyte market. The human cellular sciences company now manages extensive laboratory facilities in the University of Virginia Research Park in Charlottesville, Virginia.  

"Beta-Pro has already established a foothold in the human pancreatic islet cell market and has consistently been able to supply diabetes researchers and transplant centers with high-quality, clinical and transplantable human islets and other pancreatic biomaterials," said Beta-Pro Principle Scientific Advisor and Professor of Surgery at the University of Virginia, Kenneth L. Brayman, M.D., Ph.D.  "Based on our success we are now broadening the focus of our cellular services to include liver biology and the needs of pharmaceutical companies in testing drugs in human hepatocyte-cell cultures."

Beta-Pro partners with leading pharmaceutical companies and research organizations including: Pfizer, Eli Lilly, Genentech, Merck, Genomics Institute of the Novartis Research Foundation (GNF), and The Broad Institute in Cambridge, Massachusetts. Beta-Pro's new laboratory is designated as a good laboratory practice (GLP) facility and is now fully operational. The company has moved its snap-frozen cell bank to the new location and will use the facility to focus on hepatocytes and other human cell applications, including drug discovery services and toxicology screening using human cells.

About Beta-ProBeta-Pro isolates and distributes human pancreatic islet cells, acinar tissue, hepatocytes, adipose-derived stem cells, mesenchymal stem cells, and other biomaterials from surplus organs not placed for whole organ transplant in GMP and GLP facilities. The company also offers custom drug discovery and toxicology testing services using human cells for potential pharmacological applications. Beta-Pro charges and recovers fees for the costs for organ procurement, processing, preservation, quality control, storage, handling, and delivery of islets, other biomaterials, and biological data. For more information, call (434) 973-9456 or visit www.betaprolabs.com. Contact:

John Kelly PR(434) 296-5577john@johnkellypr.com
'/>"/>

SOURCE Beta-Pro LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
2. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
3. Hoya Vision Care Expands in Czech Republic
4. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
5. InVitria Expands Sales Team
6. Enerkem Expands Executive Management Team
7. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
8. Supelco(R) Expands Ascentis(R) Express HPLC Columns Line for High-Speed and High-Efficiency Separations
9. BioElectronics Corp Aggressively Expands Sales into Middle East
10. Quintiles Expands Base for Growing Asia-Pacific Operations
11. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, ... cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using ... Salimetrics’ SalivaLab , the relationship between insulin and other relevant biomarkers can ...
(Date:2/23/2017)... LOS ANGELES , Feb. 23, 2017  Capricor Therapeutics, ... cardiac and other medical conditions, today announced that Linda Marbán, ... at two upcoming investor conferences: Cowen ... 2017 at 10:00 am ET Boston, MA ... 14, 2017 at 9:00 am PT (12:00 pm ET) ...
(Date:2/23/2017)... and SAN FRANCISCO , ... privately-held regenerative medicine company, and Beyond Type 1, a ... type 1 diabetes, today announced a grant from Beyond ... functional cure for type 1 and other insulin-requiring diabetes.  ... has been developing innovative stem cell-derived cell replacement therapies ...
Breaking Biology Technology:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/26/2017)... -- Acuity Market Intelligence today released the 2017 "Ten ... characterizes 2017 as a "breakout" year for biometrics ... new understanding of the potential benefits these technologies ... are often perceived as threats to privacy and ... Acuity Market intelligence. "However, taken together these technologies ...
Breaking Biology News(10 mins):